Aytu biopharma, inc continues availability of adzenys xr-odt(r) as the only fda-approved orally disintegrating tablet (odt) medication that is bioequivalent to adderall xr(r) for adhd patients

Aytu rxconnect providing access relief to patients amid ongoing generic adderall® supply disruption englewood, co / accesswire / january 10, 2023 / millions of adhd patients in the united states rely on fda approved treatments to control their adhd symptoms and many of them are currently struggling to fill their prescription due to a prolonged supply disruption for generic adderall xr (mixed salts of a single-entity amphetamine product) extended-release capsules, cii. many of these patients may not be aware that there's an fda-approved, bioequivalent treatment option which is widely available.
AYTU Ratings Summary
AYTU Quant Ranking